intussception with the ileum extending into the descending colon. Multiple well defined hypo-echoic lesions were demonstrated within the bowel wall suggesting a lymphoma. A laparotomy was performed and a very thickened distal terminal ileum and caecum was noted. No bowel biopsies were obtained because of concern about perforation. Biopsies from multiple lymph nodes showed reactive changes without clonality. The intussusception was reduced and she made an uneventful recovery. Subsequent morbidity has included marked sub-mental infective adenitis requiring surgical drainage on two occasions. She remains on monthly IVIG replacement without abdominal symptoms or signs. Annual ultrasound abdominal screening continues to demonstrate multiple mesenteric and bowel wall nodes.
Next generation sequencing in the index patient (HC), her sibling and mother show a heterozygous pathogenic variant (based on ACMG guidelines) in the PIK3CD gene (c.3061G>A : p.Glu1021Lys) which has been confirmed by Sanger sequencing. APDS is caused by heterozygous gainof-function mutations in PIK3CD that induce hyper-activation of the protein products p110δ or p85α (respectively). APDS displays features of both immune deficiency and of immune dysregulation as demonstrated in this kindred. Methods: An audit of patient outcomes was conducted 3 years following the introduction of SCIg at Concord Hospital, Sydney.
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Results: 11 patients were commenced on SCIg over 3 years, and 1 patient transferred from a paediatric centre. Of the 11 patients who initiated treatment at Concord, 1 withdrew prior to completion of training due to external factors. Patients were assessed as competent to self-administer SCIg after 3-6 weekly training sessions. SCIg products prescribed included Evogam (4 patients) and Hizentra (7 patients), using an approximate 1:1 dose conversion from IVIg product. Patients were provided with pumps and consumables. 3 patients required withdrawal of SCIg and recommencement of IVIg due to cutaneous reactions, life-threatening sepsis or patient preference. Trough levels of patients on SCIg will be presented.
At 3 years, 8 patients remain on SCIg, with half infusing once per week and half infusing on 2 days/week. Patients predominantly prefer administration via an infusion pump, with a minority of patients adopting the 'push' technique.
Conclusion:
Although SCIg is a safe and established therapy, our audit reveals a relatively high rate of treatment withdrawal in a small group of patients with primary immunodeficiency. SCIg represents an effective method of IRT in carefully selected patients, although close monitoring of trough levels and adverse events is mandated. New Zealand Immunologists were invited to recruit patients with HAE and AAE to the audit or those identified as having Berinert ® for hereditary or acquired angioedema. Participants were consented, their angioedema related health information was collected and they were invited to take part in telephone or face to face interviews about their experience of healthcare.
Twenty-one patients with hereditary angioedema were recruited, three of whom had acquired angioedema C1 inhibitor deficiency. Three patients were diagnosed prior to the onset of symptoms due to the diagnosis of a family member with the disease by screening family members. The average diagnostic delay was 12.9 years. Variation in delay between different types of HAE, with the greatest mean delay being in Type 1 HAE at 18.5 years, 13 years in type 2 HAE, and 3.6 years in AAE.
Within the cohort of 21 patients there were reports of 4 deaths of family members due to HAE. The majority of patients 19/21 (90%) had a written plan to present to the emergency department. Few (24%) had a Medic Alert ® bracelet. In 2015 there were a total of 217 HAE attacks in 16 patients. Five patients (24%) were asymptomatic. Only one patient had angioedema of the upper airway in 2015 but did not require intubation. Six patients had 136 abdominal attacks; some with high frequency (range 1-52). Four patients said HAE had no impact on their life, 10 had minor impact, and 4 moderate and 3 described it as severe. This study characterises a cohort of AAE and HAE patients in New Zealand.
P83 QUALITY OF LIFE (QOL) ASSESSMENTS FOLLOWING THE USE OF PROPHYLACTIC C1 ESTERASE INHIBITOR CONCENTRATE IN PATIENTS WITH SEVERE HEREDITARY ANGIOEDEMA
A Merry, D Heyworth-Smith, C Kennedy, S Robertson and L James Greenslopes Private Hospital, Brisbane, Australia Introduction: Hereditary Angioedema (HAE) is a rare genetic condition resulting in a deficiency in C1 inhibitor protein and is characterised by both provoked and unprovoked episodes of angioedema. In a severe phenotype patients may experience repeated and frequent facial or limb angioedema, severe and recurrent abdominal pain and a risk of death by asphyxiation as a result of upper airway angioedema. The relentless nature of this condition with frequent and debilitating attacks along with previous 'on-demand' treatment requiring a hospital presentation for each attack has a profound impact on the quality of life for this patient group.
In 2016 the National Blood Authority (NBA) allowed for the routine supply of C1 inhibitor concentrate to HAE patients experiencing eight or more acute attacks per month. With appropriate training patients are able to self administer treatment at home thus avoiding hospital presentations. This change in treatment is predicted to provide a dramatic change to the QOL for this patient group.
Methods: HAE patients completed a HAE-QoL score pre and post the commencement of prophylactic use of C1 inhibitor concentrate, along with school/work attendance and documentation of disease activity.
Summary of results:
Following prophylactic use of C1 inhibitor concentrate, we have seen a marked reduction in disease activity and resultant improvement in quality of the life as measured by HAE-QoL score and school/work attendance.
Conclusions:
The availability of prophylactic use of C1 inhibitor concentrate in HAE patients with a severe phenotype has had a significant beneficial effect on the quality of life of this patient group. 
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